F
Frans Boomsma
Researcher at Erasmus University Rotterdam
Publications - 207
Citations - 11161
Frans Boomsma is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Angiotensin II & Heart failure. The author has an hindex of 55, co-authored 207 publications receiving 10805 citations. Previous affiliations of Frans Boomsma include Steno Diabetes Center & Erasmus University Medical Center.
Papers
More filters
Journal ArticleDOI
Renal function, neurohormonal activation, and survival in patients with chronic heart failure
Hans L. Hillege,Armand R. J. Girbes,Pieter J de Kam,Frans Boomsma,Dick de Zeeuw,Andrew Charlesworth,John R. Hampton,Dirk J. van Veldhuisen +7 more
TL;DR: Impaired renal function (GFR(c)) is a stronger predictor of mortality than impaired cardiac function (LVEF and New York Heart Association class) in advanced CHF, and it is associated with increased levels of N-terminal ANP.
Journal ArticleDOI
Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan
TL;DR: A low-sodium diet and HCT are equally efficacious in reducing proteinuria and BP when added to a regimen containing losartan and especially seem to benefit individuals who are resistant to RAAS blockade.
Journal ArticleDOI
Differential release of amino acids, neuropeptides, and catecholamines from isolated nerve terminals.
Matthijs Verhage,Harvey T. McMahon,W.E.J.M. Ghijsen,Frans Boomsma,Greet Scholten,Victor M. Wiegant,David G. Nicholls +6 more
TL;DR: It is concluded that neuropeptide release is triggered by small elevations in the Ca2+ concentration in the bulk cytoplasm, whereas secretion of amino acids requires higher elevations, as produced in the vicinity of Ca2- channels.
Journal ArticleDOI
Angiotensin-(1–7) Attenuates the Development of Heart Failure After Myocardial Infarction in Rats
Annemarieke E. Loot,Anton J.M. Roks,Robert H. Henning,René A. Tio,Albert J. H. Suurmeijer,Frans Boomsma,Wiek H. van Gilst +6 more
TL;DR: Angiotensin-(1–7) preserved cardiac function, coronary perfusion, and aortic endothelial function in a rat model for heart failure.
Journal ArticleDOI
Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study
TL;DR: It is suggested that spironolactone safely adds to the reno- and cardiovascular protective benefits of treatment with maximally recommended doses of ACE inhibitor and ARB by reducing albuminuria and blood pressure in type 2 diabetic patients with nephropathy.